Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Agnosia × Clonidine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 3 Neoplasms 2 Synovial Cyst 1 Spondylosis 1 Spondylolisthesis 1 Spinal Stenosis 1 Radiculopathy 1 Pain, Postoperative 1 Neoplasms, Second Primary 1 Musculoskeletal Diseases 1 Malignant Neoplasms of Male Genital Organs 1 Intervertebral Disc Displacement 1 Intervertebral Disc Degeneration 1 Hot Flashes 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Agnosia 1

Interventions

Bupivacaine 9 Ketamine 8 Analgesics, Opioid 7 Ropivacaine 6 Fentanyl 6 Dexmedetomidine 6 Anesthesia, General 6 Acetaminophen 6 Morphine 5 Lidocaine 5 Acupuncture Therapy 5 Surveys and Questionnaires 4 Pregabalin 4 Ethanol 4 Anesthesia, Local 4 parecoxib 3 Tramadol 3 Sodium Chloride 3 Saline Solution 3 Propofol 3 Ketorolac 3 Control Groups 3 Anesthetics, Local 3 Analgesia, Epidural 3 trimebutine 3-thiocarbamoylbenzenesulfonate 2 Transcutaneous Electric Nerve Stimulation 2 Tea 2 Radiofrequency Ablation 2 Magnesium Sulfate 2 Levobupivacaine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07092566 2026-01-20

R.E.C.K vs Exparel in Robotic Nephrectomy

Wake Forest University Health Sciences

Phase 3 Recruiting

Agnosia, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡